- no comment
CYTO-CHIP shows improvement in median OS from 12.1 to 18.8 months.
Independent predictors are easy to assess.
Direct pelvic mass guidelines to primary care too.
Data show up to 20% higher uptake among adults, adolescents and children.
A paired cohort study of community-dwelling middle-aged and older adults.
Final data from a multicenter phase 2 trial.
AUA does not recommend prophylaxis beyond 24 hours.
With expression in 82.5% of invasive breast cancers, GATA-3 has strong diagnostic potential.
Evaluation of a score based on 23 single-nucleotide polymorphisms.
Fewer illnesses, briefer symptoms in babies receiving higher dose.
Low complication rates, rapid recovery, and excellent graft function reported.
Long-term study identifies multiple prognostic markers in patients undergoing TORS.
Child's ASD risk increases with maternal antidepressant exposure.
Clinicians treating very young, febrile infants with suspected UTI should forgo focus on HRV.
Several societies review what we know after 164 cases.